[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100628906":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":11,"centralContacts":32,"locations":38,"responsibleParty":55,"collaborators":11,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":59,"sex":65,"minAge":66,"maxAge":67,"enrollmentInfo":68,"targetDuration":11,"studyType":71,"phases":72,"briefSummary":75,"conditions":76,"keywords":78,"overallStatus":82,"whyStopped":11,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Biocells Medical","INDUSTRY",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Neuroinduced Mesenchymal Stem Cells","EXPERIMENTAL",null,[13],"Drug: Intrathecal infusion",{"label":15,"type":10,"description":11,"interventionNames":16},"Mesenchymal Stem Cell Derived Exosomes",[17],"Drug: Intranasal infusion",{"label":19,"type":20,"description":11,"interventionNames":21},"Saline solution","PLACEBO_COMPARATOR",[17],[23,28],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":11},"DRUG","Intrathecal infusion","200,000,000 neuroinduced mesenchymal stem cells administered via intravenous infusion.",[9],{"type":24,"name":29,"description":30,"armGroupLabels":31,"otherNames":11},"Intranasal infusion","Intranasal infusion of purified exosomes derived from mesenchymal stem cells",[15,19],[33],{"name":34,"role":35,"phone":36,"phoneExt":11,"email":37},"Andrei Peskau","CONTACT","+48452365311","info@biocellsmedical.com",[39],{"facility":40,"status":11,"city":41,"state":11,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"BioCells Medical","Warsaw","02-797","Poland","PL",{"type":46,"coordinates":47},"Point",[48,49],21.01178,52.22977,{"lat":49,"lon":48},[52],{"name":53,"role":35,"phone":54,"phoneExt":11,"email":37},"Anita Gerder","+48223074882",{"type":56,"investigatorFullName":34,"investigatorTitle":5,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","100628906","phase-1-evaluation-of-the-safety-and-preliminary-efficacy-of-neuroinduced-mesenchymal-stem-cells-and-exosome-therapy-in-patients-with-spinocerebellar-palsy-100628906",false,"NCT07467733","Evaluation of the Safety and Preliminary Efficacy of Neuroinduced Mesenchymal Stem Cells and Exosome Therapy in Patients With Spinocerebellar Palsy","Phase I\u002FII Randomized Controlled Study Evaluating the Safety and Preliminary Efficacy of Neuroinduced Mesenchymal Stem Cells and Exosome Therapy in Patients With Spinocerebellar Palsy","NEURO-SCP","Inclusion Criteria:\n\nClinical diagnosis of spinocerebellar palsy confirmed by neurological examination; Disease duration ≤10 years; Ability to provide informed consent.\n\nExclusion Criteria:\n\nSevere systemic illness; Active infection; History of malignancy within 5 years; Prior stem cell therapy; Pregnancy or breastfeeding.","ALL","18 Years","45 Years",{"count":69,"type":70},90,"ESTIMATED","INTERVENTIONAL",[73,74],"PHASE1","PHASE2","This clinical study aims to evaluate the safety and preliminary therapeutic potential of mesenchymal stem cell-derived therapies in patients diagnosed with spinocerebellar palsy. The investigational treatment includes neuroinduced mesenchymal stem cells and their derived exosomes administered via intravenous and intranasal infusion.",[77],"Spinocerebellar Ataxia - All Sub-types",[79,80,81],"ataxia","mesenchymal stem cells","exosomes","NOT_YET_RECRUITING","2026-03-09",{"date":85,"type":86},"2026-03-12","ACTUAL",{"date":88,"type":70},"2026-06-01",{"date":90,"type":70},"2029-06-01",{"name":5,"class":6},1]